Hikma/Vectura’s generic Advair delayed in the US
US regulators have upheld a prior decision rejecting Hikma and Vectura’s generic formulation of GlaxoSmithKline’s asthma and chronic obstructive pulmonary syndrome therapy Advair Diskus.
Read More
Tag: Advair
GSK books solid results on weak pound, new products
GlaxoSmithKline has booked a 36 percent rise (14 percent at constant exchange rates) in core profit to £7.8 billion for 2016, driven by a 17 percent leap (6 percent at CER) in revenues to £27.9 billion.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
